AA
CNST

AlphaCentric Advisors’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

AlphaCentric Advisors’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,000
Closed -$94K – 254
2021
Q1 		$94K Hold
4,000
– – 0.03% 160
2020
Q4 		$115K Buy
+4,000
New +$101K 0.05% 106

Other funds holding CNST

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AlphaCentric Advisors's CNST Position: Q2 2021 in Review

AlphaCentric Advisors sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 4,000 shares — an estimated $94K sold.

AlphaCentric Advisors first reported a position in CNST in Q4 2020 and held it in 2 quarters. The position peaked at $115K in Q4 2020. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

  • AlphaCentric Advisors reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • AlphaCentric Advisors sold 4,000 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $94K.
  • AlphaCentric Advisors first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2020 and held it in 2 quarters.
  • AlphaCentric Advisors's Constellation Pharmaceuticals, Inc. position peaked at $115K in Q4 2020.
  • 153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on AlphaCentric Advisors's 13F filing for Q2 2021, filed 9 Mar 2022.